Repurposing of 8-Hydroxyquinoline-Based Butyrylcholinesterase and Cathepsin B Ligands as Potent Nonpeptidic Deoxyribonuclease I Inhibitors

ChemMedChem. 2022 Mar 4;17(5):e202100694. doi: 10.1002/cmdc.202100694. Epub 2022 Feb 3.

Abstract

A library of 31 butyrylcholinesterase (BChE) and cathepsin B (CatB) inhibitors was screened in vitro for inhibition of deoxyribonuclease I (DNase I). Compounds 22, 8 and 7 are among the most potent synthetic non-peptide DNase I inhibitors reported to date. Three 8-hydroxyquinoline analogues inhibited both DNase I and BChE with IC50 values below 35 μM and 50 nM, respectively, while two nitroxoline derivatives inhibited DNase I and Cat B endopeptidase activity with IC50 values below 60 and 20 μM. Selected derivatives were screened for various co-target binding affinities at dopamine D2 and D3 , histamine H3 and H4 receptors and inhibition of 5-lipoxygenase. Compound 8 bound to the H3 receptor and is highlighted as the most promising multifunctional ligand with a favorable pharmacokinetic profile and one of the most potent non-peptide DNase I inhibitors. The present study demonstrates that 8-hydroxyquinoline is a structural fragment critical for DNase I inhibition in the presented series of compounds.

Keywords: Butyrylcholinesterase; Cathepsin B; DNA; DNA cleavage; Deoxyribonuclease I.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholinesterase / metabolism
  • Butyrylcholinesterase* / metabolism
  • Cathepsin B*
  • Cholinesterase Inhibitors / chemistry
  • Cholinesterase Inhibitors / pharmacology
  • Deoxyribonuclease I / chemistry
  • Deoxyribonuclease I / pharmacology
  • Ligands
  • Molecular Docking Simulation
  • Oxyquinoline
  • Structure-Activity Relationship

Substances

  • Cholinesterase Inhibitors
  • Ligands
  • Oxyquinoline
  • Acetylcholinesterase
  • Butyrylcholinesterase
  • Deoxyribonuclease I
  • Cathepsin B